TABLE 2.

Association of mRNA expression of related inhibitor protein targets with patient survival. Gene expression in ductal breast carcinoma stroma was correlated with patient survival at 5 years. Patients were grouped according to their survival status and gene expression was compared by t test. Fold change represents average gene expression in patients reported as deceased at 5 years relative to those alive at 5 years. Significant changes are highlighted in bold

Rank	Drug [Concentration]	Robust Z-Score	Protein target	Gene name	Reporter ID	5 Year t Test	Survival P-value	Q-value	Fold change
3	ARQ-092 [10 μmol/L]	−1.76	PKB/Akt	AKT1	207163_s_at	1.895	0.033	1.460	1.13
				AKT2	203808_at	0.650	0.260	1.015	1.02
				AKT3	212607_at	0.500	0.311	1.001	1.07
5	Gö 6983 [10 μmol/L]	−1.68	PKCs	PRKCA	215194_at	1.874	0.035	1.450	1.04
				PRKCB	209685_s_at	−1.296	0.893	0.978	−1.27
				PRKCG	206270_at	−1.204	0.880	0.976	−1.04
				PRKCD	202545_at	−1.180	0.876	0.975	−1.12
8	(R)-Crizotinib [1 μmol/L]	−1.54	c-Met,	MET	203510_at	1.811	0.040	1.402	1.42
			ALK	ALK	208211_s_at	0.854	0.200	1.064	1.03
9	Bisindolylmaleimide I [10 μmol/L]	−1.52	PKCs	PRKCA	215194_at	1.874	0.035	1.450	1.04
				PRKCB	209685_s_at	−1.296	0.893	0.978	−1.27
				PRKCG	206270_at	−1.204	0.880	0.976	−1.04
				PRKCD	202545_at	−1.180	0.876	0.975	−1.12
				PRKCE	206248_at	0.652	0.260	1.015	1.03
11	AG-825 [10 μmol/L]	−1.43	ErbB2	ERBB2	210930_s_at	1.781	0.042	1.407	1.05
14	LOXO-101 [1 μmol/L]	−1.35	Trk family	NTRK1	208605_s_at	2.619	0.006	1.905	1.06
15	ML-9 [10 μmol/L]	−1.30	Multi	AKT1	207163_s_at	1.895	0.033	1.460	1.13
			kinase	AKT2	203808_at	0.650	0.260	1.015	1.02
				AKT3	212607_at	0.500	0.311	1.001	1.07
				MYLK1	not in database
				MYLK2	not in database
				MYLK3	217623_at	2.067	0.025	1.533	1.03
				MYLK4	not in database
24	ARQ-092 [1 μmol/L]	−1.03	PKB/Akt	AKT1	207163_s_at	1.895	0.033	1.460	1.13
				AKT2	203808_at	0.650	0.260	1.015	1.02
				AKT3	212607_at	0.500	0.311	1.001	1.07